TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03106311

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: assessment of beta subunit of human chorionic gonadotropin
Description: Vaginal washing fluid will be collected and sent for measurement of beta subunit of human chorionic gonadotropin

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: assessment of beta subunit of human chorionic gonadotropin
Description: Vaginal washing fluid will be collected and sent for measurement of beta subunit of human chorionic gonadotropin
Study: NCT03370900

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Testing
Description: Participants either received 20 case testing with or without feedback

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Testing
Description: Participants either received 20 case testing with or without feedback

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Testing
Description: Participants either received 20 case testing with or without feedback
Study: NCT02192411

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: 1/4 dose lidocaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: 1/4 dose lidocaine
Study: NCT00919321

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Pneumococcal polysaccharide vaccine (PPV)
Description: One intramuscular injection
Study: NCT02253446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Piroxicam
Description: 20 mg of piroxicam (Feldene ampoule-Pfizer-France) intramuscularly (IM) was given 200 patients,

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac Sodium
Description: Second Group: Diclofenac sodium 75mg (Miyadren ampoule-bulb-Yavuz Istanbul) intramuscularly (IM) was given 200 patients.
Study: NCT03038880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faricimab
Description: Faricimab was administered via IVT injections as specified during the treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faricimab
Description: Faricimab was administered via IVT injections as specified during the treatment period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: Ranibizumab was administered via IVT injections as specified during the treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sham Procedure
Description: The sham was a procedure that mimicked an IVT injection and involved the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. It was administered to participants in the faricimab treatments arms at applicable visits to maintain masking among treatment arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sham Procedure
Description: The sham was a procedure that mimicked an IVT injection and involved the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. It was administered to participants in the faricimab treatments arms at applicable visits to maintain masking among treatment arms.
Study: NCT02538978

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Bone Marrow Concentrate (aBMC)
Description: Aspirated bone marrow will be processed by centrifugation, separating out a concentrate (aBMC) comprising primarily white blood cells and platelets. These cells will be injected i.m. to loci determined by the operating physician using imaging and vascular flow criteria.~Device: SurgWerks-CLI Kit~Device: VXP System

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Control (diluted autologous peripheral blood)
Description: Diluted peripheral blood prepared in a blinded fashion to resemble bone marrow will be injected intramuscularly per the same procedure used for the Experimental Device Arm.
Study: NCT04075032

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pomegranate extract
Description: Pomegranate extract consumption (900 mg/day) for 4 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pomegranate extract
Description: Pomegranate extract consumption (900 mg/day) for 4 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (microcrystalline cellulose) consumption (900 mg/day) for 4 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (microcrystalline cellulose) consumption (900 mg/day) for 4 weeks
Study: NCT02885025

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Broccoli Sprout Extract
Description: Broccoli Sprout Extract contains the antioxidant Sulforaphane which is the active ingredient being studies.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Broccoli Sprout Extract
Description: Broccoli Sprout Extract contains the antioxidant Sulforaphane which is the active ingredient being studies.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluticasone nasal
Description: fluticasone is a nasal steroid that is currently approved for treatment of allergic rhinitis.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluticasone nasal
Description: fluticasone is a nasal steroid that is currently approved for treatment of allergic rhinitis.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: broccoli sprout extract placebo
Description: a tablet similar to the actual broccoli sprout extract though without BSE.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: broccoli sprout extract placebo
Description: a tablet similar to the actual broccoli sprout extract though without BSE.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: normal saline nasal spray
Description: normal saline to replace nasal fluticasone in specific arms of the study

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline nasal spray
Description: normal saline to replace nasal fluticasone in specific arms of the study
Study: NCT02118961

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed (DTaP vaccine, BK1301)
Description: 0.5 mL, subcutaneous injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Adsorbed Diphtheria-Tetanus Combined Toxoid (DT toxoid)
Description: 0.1 mL, subcutaneous injection
Study: NCT01715740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chinese Herbal Medicine (CHM)
Description: Each CHM capsule, weighing 500mg, consists of XFS 250 mg and QSFFT 250 mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Encapsulated powder with similar taste, color, odor to intervention Chinese herbal medicine
Study: NCT02869880

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced Pre-Consent Discussion
Description: The enhanced pre-consent discussion intervention is a tool that includes both textual and graphical information regarding the trial and an interactive component designed to initiate and facilitate conversations between all parties in the decision-parent, patient, healthcare provider and research staff.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Pre-consent Discussion
Description: Standard pre-consent discussion for a clinical trial
Study: NCT01554241

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: D3 2000 IU/day
Description: 2000 IU/day D3

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: D3 4000 IU/day
Description: vitamin D3 4000 IU/day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: D3 50,000 IU weekly
Description: vitamin D3 50,000 IU/week

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin D3 800 IU/day
Description: vitamin D3 800 IU/day
Study: NCT01524796

Intervention type: OTHER
Intervention: No intervention. Non-interventional study
Description: No intervention. Non-interventional study
Study: NCT02248519

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open Gastrectomy
Description: Patients allocated to the 'Open Gastrectomy' group will receive distal or total gastrectomy via laparotomy. This group is considered the control group

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Gastrectomy
Description: Patients allocated to the 'Laparoscopic Gastrectomy' group will undergo distal or total gastrectomy via laparoscopy. If laparoscopic resection does not seem feasible during surgery, the procedure may be converted to an open gastrectomy.
Study: NCT02154698

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 22-gauge Standard Needle
Description: Acquisition of lymph nodes samples using the 22-gauge Standard Needle, following subject-sedation and the introduction of an EBUS scope into the airway.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 22-gauge ProCore Needle
Description: Acquisition of lymph nodes samples using the 22-gauge ProCore Needle, following subject-sedation and the introduction of an EBUS scope into the airway.
Study: NCT00074048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL22
Description: Dosing via IV on Days 1,3, and 5.
Study: NCT03605485

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal Pillows CPAP mask
Description: Investigative Nasal pillows Mask to be used for OSA therapy
Study: NCT01897688

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Islet Cell Transplant
Study: NCT01106690

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: One matching placebo capsule orally (by mouth) once daily for 26 weeks with stable doses of metformin and pioglitazone.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Description: One 100 mg or 300 mg over-encapsulated tablet orally once daily for 52 weeks with stable doses of metformin and pioglitazone.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Description: One 100 mg or 300 mg over-encapsulated tablet orally once daily for 52 weeks with stable doses of metformin and pioglitazone.

Intervention type: DRUG
Group type: OTHER
Intervention: Sitagliptin
Description: One 100 mg over-encapsulated tablet orally once daily beginning at Week 26 until Week 52 with stable doses of metformin and pioglitazone.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: The patient's stable dose of metformin background therapy should be continued throughout the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: The patient's stable dose of metformin background therapy should be continued throughout the study.

Intervention type: DRUG
Group type: OTHER
Intervention: Metformin
Description: The patient's stable dose of metformin background therapy should be continued throughout the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: The patient's stable dose of pioglitazone background therapy should be continued throughout the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: The patient's stable dose of pioglitazone background therapy should be continued throughout the study.

Intervention type: DRUG
Group type: OTHER
Intervention: Pioglitazone
Description: The patient's stable dose of pioglitazone background therapy should be continued throughout the study.
Study: NCT00099333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exenatide
Description: Exenatide 5 mcg subcutaneously injected twice daily for 4 weeks; then 10 mcg subcutaneously injected twice daily for 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Insulin will be taken according to the subject's current regimen
Study: NCT00998296

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW 2992
Description: EGFR inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBF 1120
Description: VEGF inhibitor
Study: NCT01291732

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: single dose of matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 135585 XX
Description: single dose of low, medium or high dose of BI 135585 XX
Study: NCT03968562

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2% Doxycycline Cream in Generic Aquaphor or Generic Aquaphor
Description: 2% Doxycline Cream in Generic Aquaphor or Generic Aquaphor will be applied topically twice during the study visit: first for 30 minutes, then for 6 hours duration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 2% Doxycycline Cream in Generic Aquaphor or Generic Aquaphor
Description: 2% Doxycline Cream in Generic Aquaphor or Generic Aquaphor will be applied topically twice during the study visit: first for 30 minutes, then for 6 hours duration.
Study: NCT00965172

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Caphosol
Description: Oral rinse of calcium phosphate solution five times daily beginning on day one of chemotherapy.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Baking Soda
Description: Oral rinse of baking soda solution as per standard of care five times daily beginning on day one of chemotherapy.
Study: NCT02052518

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental
Description: These participants will receive the enhanced intervention including decision support and problem solving skills in addition to the standard of care for the individuals in the Nuturing Family Network Home Visition Program

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Experimental
Description: These participants will receive the enhanced intervention including decision support and problem solving skills in addition to the standard of care for the individuals in the Nuturing Family Network Home Visition Program
Study: NCT03478709

Intervention type: OTHER
Intervention: volume expansion
Description: Volume expansion when the patient has a dependent preload evaluated by a positive leg lever test (variation of more than 10% of the VES). It corresponds to the intravenous administration of 500 ml of Ringer lactate over 10 min.

Intervention type: OTHER
Intervention: norepinephrine
Description: Vasopressor agent when the patient has persistent arterial hypotension related to postoperative vasoplegia syndrome. Norepinephrine is administered during persistent hypotension (MAP \<60mmHg) despite volume expansion. It corresponds to continuous intravenous norepinephrine administration to obtain a MAP of more than 70 mmHg
Study: NCT03687060

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Knowledge assessment
Description: Investigators will conduct semi-structured interviews with medical directors, clinical leadership and all participating physicians to gain insight on knowledge about and barriers to prescribing statins for people living with HIV. People living with HIV will participate in focus groups.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Knowledge assessment
Description: Investigators will conduct semi-structured interviews with medical directors, clinical leadership and all participating physicians to gain insight on knowledge about and barriers to prescribing statins for people living with HIV. People living with HIV will participate in focus groups.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Knowledge assessment
Description: Investigators will conduct semi-structured interviews with medical directors, clinical leadership and all participating physicians to gain insight on knowledge about and barriers to prescribing statins for people living with HIV. People living with HIV will participate in focus groups.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Education Intervention
Description: Education intervention will be adapted from the the findings of these interviews and focus groups.~Clinics will be randomized to receive the education intervention and feedback implementation strategies at different times.~Medical directors and providers will receive a brief educational intervention about cardiovascular disease risk in people living with HIV. Providers will additionally receive a web-based survey before and after the education intervention.~Patients will receive pamphlets tailored to the effects of cardiovascular disease treatment for people living with HIV.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Provider Feedback
Description: Six months after the education intervention, providers will receive monthly emails with feedback regarding their rates of prescribing statins, with language targeted at increasing motivation to prescribe by leveraging social norms and self-image.
Study: NCT03385980

Intervention type: OTHER
Intervention: Proteomic analysis
Description: Proteomic analysis of tissues collected from all sites of disease, guided by either imaging performed prior to the patient's death or post-mortem findings. Peripheral blood mononuclear cells (PBMC) will be collected with the purpose of identifying somatic changes occurring specifically in the tumor cells and not in normal DNA of the same patient.
Study: NCT04341870

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sarilumab
Description: Sarilumab: 400 mg in a 1 hour - I.V. infusion on D1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarilumab
Description: Sarilumab: 400 mg in a 1 hour - I.V. infusion on D1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Azithromycin: oral administration, 500mg on D1 then 250mg QD on D2 to D5 (total duration 5 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine: oral administration, 600mg QD (200mg TID) from D1 to D10 (total duration 10 days)
Study: NCT03529591

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Selective laser trabeculoplasty (SLT)
Description: In this study, treatment naive patients with bilateral ocular hypertension or primary open angle glaucoma are treated with 180 degrees SLT in one eye and 360 degrees SLT in the contralateral eye. The primary outcome measure is assessing the response to SLT in both eyes and comparing the intraocular pressure outcomes between the two eyes of each patient.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Selective laser trabeculoplasty (SLT)
Description: In this study, treatment naive patients with bilateral ocular hypertension or primary open angle glaucoma are treated with 180 degrees SLT in one eye and 360 degrees SLT in the contralateral eye. The primary outcome measure is assessing the response to SLT in both eyes and comparing the intraocular pressure outcomes between the two eyes of each patient.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Selective laser trabeculoplasty
Description: In this study, treatment naive patients with bilateral ocular hypertension or primary open angle glaucoma are treated with 180 degrees SLT in one eye and 360 degrees SLT in the contralateral eye. The primary outcome measure is assessing the response to SLT in both eyes and comparing the intraocular pressure outcomes between the two eyes of each patient.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Selective laser trabeculoplasty
Description: In this study, treatment naive patients with bilateral ocular hypertension or primary open angle glaucoma are treated with 180 degrees SLT in one eye and 360 degrees SLT in the contralateral eye. The primary outcome measure is assessing the response to SLT in both eyes and comparing the intraocular pressure outcomes between the two eyes of each patient.
Study: NCT03678519

Intervention type: DIAGNOSTIC_TEST
Intervention: Pulmonary function test
Description: Pulmonary Function tests using Spirometry. It will show following indices of ventilatory functions: Forced vital capacity (FVC), Forced expiratory volume in the 1st second (FEV1) and Forced expiratory volume in the 1st second as a percentage of the Forced vital capacity (FEV1/FVC %).
Study: NCT02309242

Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: Neuropsychological assessment, MRI
Description: All subjects will be imaged (MRI) on the same 3T Philips scanner with a 32-channel phased-array head coil, located in the radiology department at UZ Leuven. For the neuropsychological assessment we will implement an extended neuropsychological assessment battery: ANT, CMS, Rey, BRIEF, WISC III, PedsQL, STAI, BDi, achenbach questionnaires
Study: NCT02106390

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningococcal group B Vaccine, rMenB+OMV NZ
Description: 4 doses administered intramuscularly on Days 1, 61, 121 and 301 with blood draw visits at Days 1, 151, 301 and 331 and who will receive reminder calls at 2 and 4 days after each vaccination visit and safety calls on Days 201 and 251.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal group B Vaccine, rMenB+OMV NZ
Description: 4 doses administered intramuscularly on Days 1, 61, 121 and 301 with blood draw visits at Days 1, 151, 301 and 331 and who will receive reminder calls at 2 and 4 days after each vaccination visit and safety calls on Days 201 and 251.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningococcal ACWY Conjugate Vaccine, MenACWY
Description: 4 doses administered intramuscularly on Days 1, 61, 121 and 301 with blood draw visits at Days 1, 151, 301 and 331 and who will receive reminder calls at 2 and 4 days after each vaccination visit and safety calls on Days 201 and 251.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal ACWY Conjugate Vaccine, MenACWY
Description: 4 doses administered intramuscularly on Days 1, 61, 121 and 301 with blood draw visits at Days 1, 151, 301 and 331 and who will receive reminder calls at 2 and 4 days after each vaccination visit and safety calls on Days 201 and 251.
Study: NCT03809104

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality-based rehabilitation programs
Description: A virtual reality (VR)-based rehabilitation program that lasts for 12 weeks, twice per week, 30 minutes per time. The program was combined with progressive resistant training and functional movement of dominant upper (UE) limb. The device of the VR including one computer, one oculus headset, and one hand-hold sensor. The rehabilitation secession contains 4 different VR games in total, including (1) Leap Motion Blocks (2) Slum Ball VR Tournament (3) VR Super Sports 10th Edition- Basketball (4) VR Super Sports 10th Edition- Soccer.